Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nyi Nyi Soe, Jason J. Ong, Xiaomeng Ma, Christopher K Fairley, Phyu Mon Latt, Jun Jing, Feng Cheng & Lei Zhang. (2018) Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness. Human Vaccines & Immunotherapeutics 14:12, pages 3010-3018.
Read now
Read now
Anita W. M. Suijkerbuijk, Robine Donken, Anna K. Lugnér, G. Ardine de Wit, Chris J. L. M. Meijer, Hester E. de Melker & Johannes A. Bogaards. (2017) The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Review of Vaccines 16:4, pages 361-375.
Read now
Read now
Wanrudee Isaranuwatchai, Donna M Graham, Lillian L Siu & Jeffrey S Hoch. (2014) Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 763-765.
Read now
Read now
Articles from other publishers (25)
Kris Doggen, Albert Jan van Hoek & Jeroen Luyten. (2023) Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella. PharmacoEconomics 41:5, pages 481-497.
Crossref
Crossref
Sangrak Bae & Sooyoun Kim. (2022) What Are the Barriers to Human Papillomavirus Vaccination for Male in South Korea?. Urogenital Tract Infection 17:3, pages 53-60.
Crossref
Crossref
Margaret Logel, Cassandra Laurie, Mariam El-Zein, Juliet Guichon & Eduardo L. Franco. (2022) A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination. Cancer Epidemiology, Biomarkers & Prevention 31:5, pages 919-931.
Crossref
Crossref
Larisa Dmitrievna Belotserkovtseva & Yulia Igorevna Mayer. 2020. Human Papillomavirus [Working Title]. Human Papillomavirus [Working Title].
Mireia Diaz, Silvia de Sanjosé, F. Xavier Bosch & Laia Bruni. (2018) Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology & Radiotherapy 23:6, pages 484-494.
Crossref
Crossref
Ellen Wolff, K. Miriam Elfström, Hedda Haugen Cange, Sofie Larsson, Helene Englund, Pär Sparén & Adam Roth. (2018) Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine 36:34, pages 5160-5165.
Crossref
Crossref
Siok Shen Ng, Raymond Hutubessy & Nathorn Chaiyakunapruk. (2018) Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine 36:19, pages 2529-2544.
Crossref
Crossref
Gillian Prue, David Grimes, Peter Baker & Mark Lawler. (2018) Access to HPV vaccination for boys in the United Kingdom. Medicine Access @ Point of Care 2, pages 239920261879969.
Crossref
Crossref
Wegene Borena, Margarethe Grünberger, Andreas Widschwendter, Karl Heinz Kraxner, Elisabeth Marth, Peter Mayr, Joerg Meier, Norman Ruth, Aida Tort Guerrero, Christian Marth & Dorothee Holm-von Laer. (2016) Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria. BMC Public Health 16:1.
Crossref
Crossref
L. Boiron, E. Joura, N. Largeron, B. Prager & M. Uhart. (2016) Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infectious Diseases 16:1.
Crossref
Crossref
Wegene Borena, Anita Luckner-Hornischer, Franz Katzgraber & Dorothee Holm-von Laer. (2016) Factors affecting HPV vaccine acceptance in west Austria: Do we need to revise the current immunization scheme?. Papillomavirus Research 2, pages 173-177.
Crossref
Crossref
Gillian Prue, Gilla Shapiro, Ruth Maybin, Olinda Santin & Mark Lawler. (2016) Knowledge and acceptance of human papillomavirus (HPV) and HPV vaccination in adolescent boys worldwide: A systematic review. Journal of Cancer Policy 10, pages 1-15.
Crossref
Crossref
E.A. Joura & S. Pils. (2016) Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?. Clinical Microbiology and Infection 22, pages S125-S127.
Crossref
Crossref
Stefanie Luckau, Tim P. Wehrs, Sven Brandau, Peter A. Horn & Monika Lindemann. (2016) Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells. Journal of Immunotherapy 39:8, pages 316-320.
Crossref
Crossref
Laurent Abramowitz, Philippe Descamps, François Denis, Marie-Aliette Dommergues, Pierre Pradat, Jean Lacau St Guily & Philippe Judlin. (2016) Papillomavirus and cancers: should we extend vaccination to boys in France?. Journal of Public Health.
Crossref
Crossref
Elissa Meites, Pamina M. Gorbach, Beau Gratzer, Gitika Panicker, Martin Steinau, Tom Collins, Adam Parrish, Cody Randel, Mark McGrath, Steven Carrasco, Janell Moore, Akbar Zaidi, Jim Braxton, Peter R. Kerndt, Elizabeth R. Unger, Richard A. Crosby & Lauri E. Markowitz. (2016) Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014. Journal of Infectious Diseases 214:5, pages 689-696.
Crossref
Crossref
CC Wang & JM Palefsky. (2016) Human papillomavirus-related oropharyngeal cancer in the HIV-infected population. Oral Diseases 22, pages 98-106.
Crossref
Crossref
Elizabeth Thurgar, Samantha Barton, Charlotta Karner & Steven J Edwards. (2016) Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technology Assessment 20:24, pages 1-486.
Crossref
Crossref
Riccardo A. Audisio, Giancarlo Icardi, Andrea M. Isidori, Carlo A. Liverani, Alberto Lombardi, Luciano Mariani, Francesco Saverio Mennini, David A. Mitchell, Andrea Peracino, Sergio Pecorelli, Giovanni Rezza, Carlo Signorelli, Giovanni Vitali Rosati & Gian Vincenzo Zuccotti. (2016) Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology 97, pages 157-167.
Crossref
Crossref
Elmar A Joura & Sophie Pils. (2015) How can we achieve HPV control in Europe?. Future Virology 10:10, pages 1125-1127.
Crossref
Crossref
Donna M. Graham, Wanrudee Isaranuwatchai, Steven Habbous, Claire de Oliveira, Geoffrey Liu, Lillian L. Siu & Jeffrey S. Hoch. (2015) A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer 121:11, pages 1785-1792.
Crossref
Crossref
Karly S. Louie, Hisham Mehanna & Peter Sasieni. (2015) Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncology 51:4, pages 341-348.
Crossref
Crossref
Peter A Newman & Ashley Lacombe-Duncan. (2014) Human papillomavirus vaccination for men: advancing policy and practice. Future Virology 9:12, pages 1033-1047.
Crossref
Crossref
L. D. Belotsercovtseva, Yu. I. Mayer & S. V. Leskova. (2014) REGIONAL VACCINATION PROGRAM FOR THE PREVENTION OF HPV-ASSOCIATED DISEASES IN THE KHMAO-YUGRA. Russian Journal of Infection and Immunity 4:2, pages 155-161.
Crossref
Crossref
Paul L. McCormack. (2014) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs 74:11, pages 1253-1283.
Crossref
Crossref